Novo Nordisk (NVO)

• Market cap: $367B
• 1 day: -0.04%
• 5 days: -3.50%
• 1 month: -2.83%
• 3 months: -24.70%
• 6 months: -34.43%
• Year to date: -5.60%
• 1 year: -30.14%
• 5 years: 168.25%
• 10 years: 282.32%

About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 72,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

8% more repeat investments, than reductions

Existing positions increased: 692 | Existing positions reduced: 641

0.43% less ownership

Funds ownership: 10.46% [Q2] → 10.03% (-0.43%) [Q3]

4% less funds holding

Funds holding: 1,840 [Q2] → 1,760 (-80) [Q3]

20% less capital invested

Capital invested by funds: $50.6B [Q2] → $40.2B (-$10.4B) [Q3]

27% less first-time investments, than exits

New positions opened: 148 | Existing positions closed: 204

31% less funds holding in top 10

Funds holding in top 10: 89 [Q2] → 61 (-28) [Q3]

32% less call options, than puts

Call options by funds: $791M | Put options by funds: $1.16B

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $105 27% upside
• Avg. target: $133 60% upside
• High target: $160 94% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

BMO Capital Evan David Seigerman 21% 1-year accuracy 4 / 19 met price target	27% upside $105	Outperform Maintained	23 Dec 2024
Cantor Fitzgerald Louise Chen 32% 1-year accuracy 46 / 143 met price target	94% upside $160	Overweight Reiterated	6 Nov 2024